BioIVT acquires donor center to bring fresh blood products to European clients

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Takasuu)
(Image: Getty/Takasuu)

Related tags Blood Preclinical services Cell

BioIVT has acquired Clinical Trials Laboratory Services, a UK-based donor center, in an aim to provide fresh blood products to clients.

Clinical Trials Laboratory Services (CTLS) provides serum, plasma, and blood collection services, with full-service cell processing capabilities on site.

With the acquisition, BioIVT will offer fresh blood and blood-derived products as well as expand its immune cell offering to clients.

Courtney Noah, BioIVT VP told us, “We were interested in expanding our footprint in Europe by offering fresh blood and blood-derived products. We already do this for our US clients and know that it is something that our European clients have a strong need for.”

Noah explained that in recent years BioIVT has worked to build a portfolio of normal and disease-state human specimens, including tissues, biofluids, and cellular products. With the acquisition of CTLS this portfolio can grow to make BioIVT a supplier of biospecimens to the global research community, he said.

All CTLS employees will join BioIVT after the acquisition and the current CTLS London headquarters will become the primary site for donor collections. The company stated that it will aim to enhance the acquired laboratory’s capabilities with a specific focus on increasing immune cell isolation abilities.

BioIVT says that per this acquisition it will have a space to provide a ‘consistent’ supply of fresh blood and blood products for research. Noah said the company will be looking to expand its collection capabilities at the CTLS site to “stay ahead of client demand.”

“We also see this as an opportunity to expand our clinical collections for disease-state donors, an area of growth for us in Europe. Another early focus of the integration will be on enhancing the laboratory capabilities for us in Europe.”

Noah said CTLS employees will be trained on additional protocols and control procedures to focus on the delivery of fresh blood-derived products across the region. 

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us


View more